ALNY vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ALNY is a standard domestic listing, while HLN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | ALNY | HLN |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Haleon plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Biotechnology | Personal Care Products |
| Market Capitalization | 60.38 billion USD | 40.14 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 1, 2004 | July 25, 2022 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of ALNY and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| 5-Day Price Return | -0.52% | 0.64% |
| 13-Week Price Return | 39.84% | -11.50% |
| 26-Week Price Return | 69.38% | -13.01% |
| 52-Week Price Return | 65.87% | -14.94% |
| Month-to-Date Return | 2.13% | -8.40% |
| Year-to-Date Return | 93.79% | -11.92% |
| 10-Day Avg. Volume | 1.08M | 19.89M |
| 3-Month Avg. Volume | 1.07M | 15.02M |
| 3-Month Volatility | 40.09% | 19.29% |
| Beta | 0.28 | 0.46 |
Profitability
Return on Equity (TTM)
ALNY
-274.21%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
ALNY has a negative Return on Equity of -274.21%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
HLN
3.26%
Personal Care Products Industry
- Max
- 33.29%
- Q3
- 19.04%
- Median
- 10.69%
- Q1
- 3.26%
- Min
- -10.45%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
ALNY
-12.96%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
ALNY has a negative Net Profit Margin of -12.96%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
HLN
12.84%
Personal Care Products Industry
- Max
- 14.65%
- Q3
- 10.84%
- Median
- 9.29%
- Q1
- 5.35%
- Min
- -0.14%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ALNY
-7.32%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
ALNY has a negative Operating Profit Margin of -7.32%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.64%
- Q3
- 16.46%
- Median
- 12.80%
- Q1
- 8.01%
- Min
- 2.98%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Return on Equity (TTM) | -274.21% | 3.26% |
| Return on Assets (TTM) | -7.41% | 1.58% |
| Net Profit Margin (TTM) | -12.96% | 12.84% |
| Operating Profit Margin (TTM) | -7.32% | 19.64% |
| Gross Profit Margin (TTM) | 83.64% | 60.75% |
Financial Strength
Current Ratio (MRQ)
ALNY
2.80
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
ALNY’s Current Ratio of 2.80 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
HLN
0.87
Personal Care Products Industry
- Max
- 4.03
- Q3
- 2.73
- Median
- 1.76
- Q1
- 1.16
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ALNY
4.10
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 4.10, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
HLN
0.53
Personal Care Products Industry
- Max
- 1.80
- Q3
- 0.78
- Median
- 0.30
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ALNY
-0.95
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
ALNY has a negative Interest Coverage Ratio of -0.95. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -3.28
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Current Ratio (MRQ) | 2.80 | 0.87 |
| Quick Ratio (MRQ) | 2.63 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 4.10 | 0.53 |
| Interest Coverage Ratio (TTM) | -0.95 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.99%
- Q3
- 2.70%
- Median
- 1.98%
- Q1
- 0.95%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HLN
954.40%
Personal Care Products Industry
- Max
- 221.40%
- Q3
- 137.27%
- Median
- 70.48%
- Q1
- 51.10%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.72% |
| Dividend Payout Ratio (TTM) | 0.00% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
ALNY
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for ALNY is currently unavailable.
HLN
20.54
Personal Care Products Industry
- Max
- 46.28
- Q3
- 31.71
- Median
- 22.50
- Q1
- 20.20
- Min
- 11.79
HLN’s P/E Ratio of 20.54 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ALNY
24.31
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
ALNY’s P/S Ratio of 24.31 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HLN
2.64
Personal Care Products Industry
- Max
- 2.59
- Q3
- 2.35
- Median
- 1.92
- Q1
- 1.18
- Min
- 0.00
With a P/S Ratio of 2.64, HLN trades at a valuation that eclipses even the highest in the Personal Care Products industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
ALNY
169.67
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
At 169.67, ALNY’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
HLN
2.11
Personal Care Products Industry
- Max
- 12.00
- Q3
- 6.22
- Median
- 2.84
- Q1
- 1.70
- Min
- 1.12
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ALNY | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 20.54 |
| Price-to-Sales Ratio (TTM) | 24.31 | 2.64 |
| Price-to-Book Ratio (MRQ) | 169.67 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 334.52 | 13.77 |